CAR T-cell therapy in highly aggressive B-cell lymphoma: emerging biological and clinical insights.
Blood
; 140(13): 1461-1469, 2022 09 29.
Article
in En
| MEDLINE
| ID: mdl-35560330
ABSTRACT
Recently, significant progress has been made in identifying novel therapies, beyond conventional immunochemotherapy strategies, with efficacy in B-cell lymphomas. One such approach involves targeting the CD19 antigen on B cells with autologous-derived chimeric antigen receptor (CAR) cells. This strategy is highly effective in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), as evidenced by recent regulatory approvals. Recent reports suggest that this is an effective strategy for high-grade B-cell lymphoma. The biological underpinnings of these entities and how they overlap with each other and DLBCL continue to be areas of intense investigation. Therefore, as more experience with CAR T-cell approaches is examined, it is interesting to consider how both tumor cell-specific and microenvironmental factors that define these highly aggressive subsets influence susceptibility to this approach.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Lymphoma, Large B-Cell, Diffuse
/
Receptors, Chimeric Antigen
Type of study:
Prognostic_studies
Limits:
Humans
Language:
En
Journal:
Blood
Year:
2022
Type:
Article